149 Aufrufe 149 0 Kommentare 0 Kommentare

    Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease

    Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease

    Bristol Myers Squibb (NYSE: BMY) today announced the launch of “Investigating Myeloma,” a multiple myeloma awareness campaign, in partnership with award-winning actor, director, producer and advocate Mariska Hargitay. This campaign spotlights the importance of ongoing scientific investigation in multiple myeloma, including an approach called CELMoD research led by BMS, defined as cereblon E3 ligase modulation. CELMoD research focuses on engaging key proteins involved in the disease for breakdown by the cell’s own protein removal system to stimulate the immune system and enhance cancer cell killing. For Mariska, this campaign is deeply personal as she reflects on how research has evolved 20 years after her father, Mickey Hargitay, passed away from the disease.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605097757/en/

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Bristol-Myers Squibb!
    Long
    55,11€
    Basispreis
    0,54
    Ask
    × 9,87
    Hebel
    Zum Produkt
    Blatt
    Short
    67,04€
    Basispreis
    0,54
    Ask
    × 9,72
    Hebel
    Zum Produkt
    Blatt
    Präsentiert von
    Im Durchschnitt erleiden 7 von 10 Kleinanlegern Verluste beim Handel mit Turbo-Zertifikaten. Turbo-Zertifikate sind hoch risikoreiche Produkte und nicht für langfristige Anlagestrategien geeignet.
    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.
    Mariska Hargitay, Investigating Myeloma (Photo by Nikolett Kustos)

    Mariska Hargitay, Investigating Myeloma (Photo by Nikolett Kustos)

    “My father was and remains my hero. Many years have passed since we lost him to multiple myeloma, but I still have questions about the disease that brought down this pillar in my life,” said Mariska. “This campaign is my chance to honor my dad, answer my questions about myeloma, and shine a light on CELMoD research, a remarkable area of scientific inquiry that has emerged since his death and is renewing hope for patients and their loved ones.”

    Mickey Hargitay was an actor, champion body builder and family man. Mariska first noticed something might be wrong at her wedding, where Mickey, always so full of life, seemed unusually tired. At the time, she believed he was just overwhelmed with emotion, but looking back now, understands it was a sign that something wasn’t right. True to his spirit, Mickey approached his myeloma diagnosis with a positive attitude and though the treatment landscape looked different than it does today, he fought with everything he had until the end. Her personal journey of reconnecting with Mickey’s story is at the heart of “Investigating Myeloma, which underscores the critical need for continued scientific investigation.

    “Listening to Mariska’s story, I felt an immediate personal connection. I lost my father to multiple myeloma many years ago, and that experience continues to shape how I approach the work we do at BMS,” said Monica Shaw, MD, Senior Vice President, Oncology Commercialization at Bristol Myers Squibb. “I had trained as a physician but was working in industry at the time of his diagnosis, and I remember how difficult it was to truly understand what his options were and how to access them. No patient or family should have to navigate that complexity on their own. That experience fuels my commitment to expanding access, simplifying the journey for patients, and accelerating awareness of new scientific approaches—like CELMoD research—that have the potential to make a meaningful difference for patients living with multiple myeloma.”

    Seite 1 von 3 





    Business Wire (engl.)
    0 Follower
    Autor folgen

    Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease Bristol Myers Squibb (NYSE: BMY) today announced the launch of “Investigating Myeloma,” a multiple myeloma awareness campaign, in partnership with award-winning actor, director, producer and advocate Mariska Hargitay. This campaign spotlights the …

    Im Durchschnitt erleiden 7 von 10 Kleinanlegern Verluste beim Handel mit Turbo-Zertifikaten. Turbo-Zertifikate sind hoch risikoreiche Produkte und nicht für langfristige Anlagestrategien geeignet.
    Profitieren Sie von unserem Alleinstellungsmerkmal als den zentralen verlagsunabhängigen Wissens-Hub für einen aktuellen und fundierten Zugang in die Börsen- und Wirtschaftswelt, um strategische Entscheidungen zu treffen.
    • ✅ Größte Finanz-Community Deutschlands
    • ✅ über 550.000 registrierte Nutzer
    • ✅ rund 2.000 Beiträge pro Tag
    • ✅ verlagsunabhängige Partner ARIVA, FinanzNachrichten und BörsenNews
    • ✅ Jederzeit einfach handeln beim SMARTBROKER+
    • ✅ mehr als 25 Jahre Marktpräsenz
    Aktien von A - Z: # A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
    wallstreetONLINE bei X wallstreetONLINE bei Instagram wallstreetONLINE bei Facebook wallstreetONLINE bei Youtube wallstreetONLINE bei LinkedIn
    Unsere Apps: Apple App Store Icon Google Play Store Icon
    Wenn Sie Kursdaten, Widgets oder andere Finanzinformationen benötigen, hilft Ihnen ARIVA gerne. 

    Unsere User schätzen wallstreet-online.de: 4.8 von 5 Sternen ermittelt aus 285 Bewertungen bei www.kagels-trading.de
    Zeitverzögerung der Kursdaten: Deutsche Börsen +15 Min. NASDAQ +15 Min. NYSE +20 Min. AMEX +20 Min. Dow Jones +15 Min. Alle Angaben ohne Gewähr.
    Copyright © 1998-2026 Smartbroker Holding AG - Alle Rechte vorbehalten.
    Mit Unterstützung von: Ariva Smartbroker+
    Daten & Kurse von: TTMzero